Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus - ScienceDirect
2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D. - ppt download
FDA Background Document Endocrinologic and Metabolic Drugs Advisory Committee Meeting October 24-25, 2018
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus | Circulation
Patient Advocacy Groups Urge FDA to Update 2008 Cardiovascular Risk in Type 2 Diabetes Guidance - Alliance for Aging Research
Pharmaceuticals | Free Full-Text | Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?
US FDA Guidance for Industry on Diabetes Therapies- Revisited
Update on CVOTs in Type 2 DM Treatment - ppt download
Diabetes Drugs | SpringerLink
L'importanza di un trattamento precoce glico-cardio-metabolico nel paziente diabetico tipo 2
HS_MAB Prag paper_abstract_ADA 2012 WEB
Summary of FDA February 2008 draft guidance and December 2008 guidance | Download Table
Cvot | PDF | Cardiovascular Diseases | Clinical Trial
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink
Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs? | Circulation
Type 2 Diabetes Drugs Can Skip Cardiovascular Outcome Trials, But Phase III Must Be Longer, Broader :: Pink Sheet
Federal Register/Vol. 73, No. 42/Monday, March 3, 2008/Notices
Alfonso Valle on Twitter: "New Decade, New FDA Guidance for Diabetes Drug Development 🔑”The story of diabetes drug development, from the glucocentric approach to the proposed 2020 Guid- ance, has been nothing
New Decade, New FDA Guidance for Diabetes Drug Development: Lessons Learned and Future Directions | Journal of the American College of Cardiology
SAC Tracker on Twitter: "What were the goals of the 2008 #CVOT guidance? How did industry implement the guidance? What does FDA note from their review of diabetes drug development programs before
Endocrinologic and Metabolic Drugs Advisory Committee Meeting October 24-25, 2018 Introductory Remarks
SAC Tracker on Twitter: "What were the goals of the 2008 #CVOT guidance? How did industry implement the guidance? What does FDA note from their review of diabetes drug development programs before
Guidance for Industry
Summary of FDA February 2008 draft guidance and December 2008 guidance | Download Table
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus | Circulation
